Yago Luis Nieto MD

Hematologic Oncology

Professor of Medicine, University of Texas

MD Anderson Cancer Center1515 Holcombe BlvdHouston, TX 77030

Dr. Nieto is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nieto's full profile Already have an account?

Summary

Dr. Yago Nieto is a hematology-oncologist with a subspecialty in stem-cell transplantation and cellular immunotherapies who practices at MD Anderson, Houston, TX. He completed his training at the University of Colorado. Dr. Nieto has extensive experience in hematopoietic stem cell transplantation and lymphoma. His scholarly contributions include multiple publications on stem cell transplantation and lymphoma treatment in high-impact journals. He has led clinical trials investigating innovative immunotherapies for various lymphomas. His other area of interest is high-dose chemotherapy for refractory germ-cell tumors. Dr. Nieto has received CMS Meaningful Use Stage 1 Certification from ClinicStation at UT MD Anderson Cancer Center for his work in 2013-2015.

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 1996 - 1999
Hospital Clínico San Carlos, MadridInternal Medicine, Medical Oncology, 1990 - 1996
Universidad de Navarra Faculty of MedicineClass of 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2027
GA State Medical License 2024 - 2027
MS State Medical License 2024 - 2027
OK State Medical License 2020 - 2027
TX State Medical License 2006 - 2027
AL State Medical License 2024 - 2026
LA State Medical License 2024 - 2026
TN State Medical License 2024 - 2026
WA State Medical License 2024 - 2026
CO State Medical License 1999 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors Start of enrollment: 2009 Jun 02
COMPLETED
PHASE2
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Start of enrollment: 2012 Oct 25
COMPLETED
PHASE1, PHASE2
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
COMPLETED
PHASE2

Publications & Presentations

PubMed

NK cell-based immunotherapy.
Mark Alexander Forsberg, Yago Nieto
Human Vaccines & Immunotherapeutics. 2026-12-01
Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy.
Yosra M Aljawai, Kai Cao, Jun Zou, Yudith Carmazzi, Amin Alousi
Bone Marrow Transplantation. 2026-08-01
Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200.
Qaiser Bashir, Peter F Thall, Jitesh Kawedia, Xun Xu, Cristina G Knape
Blood Advances. 2026-07-31

Journal Articles

Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs
Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature

Abstracts/Posters

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Yago Nieto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

MD Anderson Research Highlights for September 5, 2025September 6th, 2025
Breakthrough Discoveries from MD Anderson: Research Highlights – September 5, 2025September 5th, 2025
Allogeneic NK Cell Therapy Achieves 92% Response Rate in LymphomaApril 7th, 2025